cytochrome P450 family 4 subfamily A member 22Genealiases: []
Q-omics provides the consensus-scored CYP4A22 profile across patient tissues and cancer cell-line models. CYP4A22 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CYP4A22 is differentially expressed in 11, with the highest sampling consensus in KIRP. Additionally, CYP4A22 RNA expression shows 12,136 significant gene co-expression associations, with the highest sampling consensus in LAML. Together, these results highlight KIRC, KIRP, and LAML as cancer lineages where CYP4A22 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP4A22 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP4A22 survival associations across molecular data types. CYP4A22 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP4A22 RNA expression–survival associations across cancer types. High CYP4A22 expression shows unfavorable associations in DLBC, but favorable associations in KIRC, HNSC, BLCA, READ and LIHC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CYP4A22 RNA expression.
This table summarizes CYP4A22 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for CYP4A22. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP4A22 shows lower tumor expression in KIRP, LIHC, KICH, KIRC, CHOL and LUSC. The KIRP box plot shows higher CYP4A22 RNA expression in normal versus tumor tissue (log2 FC = −4.952, t-test p < 0.001).
This table shows molecular features associated with CYP4A22 in patient tissues and cancer cell lines. In patient samples, CYP4A22 shows the broadest associations at the RNA and protein expression levels, with LAML recurring as the lineage with the largest associated feature set. In cancer cell lines, CYP4A22 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and OVARY.
